Biodeal Pharmaceuticals Raises INR110 Cr for Infrastructure and Nutraceuticals

Biodeal Pharmaceuticals Receives INR110 Cr. Investment From Piramal Alternatives

Biodeal Pharmaceuticals' Investment from Piramal Alternatives

Key Highlights:

  • Investment: Biodeal Pharmaceuticals, a contract development and manufacturing company based in Himachal Pradesh, India, received an INR110 Cr investment from Piramal Alternatives.
  • Infrastructure and Capacity Enhancement: The funds will be used to improve infrastructure, upgrade technology, and establish a dedicated nutraceuticals manufacturing facility.
  • Integrated Pharmaceutical Manufacturing: Biodeal Pharmaceuticals offers pharmaceuticals, cosmetics, and nutraceuticals through contract manufacturing services and its own brands.

Biodeal Pharmaceuticals' Target Market

  • Global Reach: Supplies products to customers across 36 countries through contract manufacturing services and its own brands.
  • Pharmaceutical and Nutraceutical Industries: Provides manufacturing and marketing services to pharmaceutical, cosmetic, and nutraceutical companies.
  • Health and Wellness Market: Offers a range of products, including vitamins, antioxidants, amino acids, and herbals, catering to specific health and wellness needs.

What Biodeal Pharmaceuticals Needs to Buy

  • Infrastructure and Technology Upgrades: Partnerships with companies specializing in infrastructure development and technology upgrades for pharmaceutical manufacturing.
  • Nutraceutical Manufacturing Equipment: Procurement of specialized equipment for the establishment of a dedicated nutraceuticals manufacturing facility.
  • Marketing and Distribution Support: Collaborations with marketing and distribution partners to expand the reach of their own brands and contract manufacturing services.